These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1588568)

  • 1. Bioreductive fluorescent markers for hypoxic cells: a study of 2-nitroimidazoles with 1-substituents containing fluorescent, bridgehead-nitrogen, bicyclic systems.
    Hodgkiss RJ; Middleton RW; Parrick J; Rami HK; Wardman P; Wilson GD
    J Med Chem; 1992 May; 35(10):1920-6. PubMed ID: 1588568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorescent markers for hypoxic cells: a study of nitroaromatic compounds, with fluorescent heterocyclic side chains, that undergo bioreductive binding.
    Hodgkiss RJ; Jones GW; Long A; Middleton RW; Parrick J; Stratford MR; Wardman P; Wilson GD
    J Med Chem; 1991 Jul; 34(7):2268-74. PubMed ID: 2066999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioreductive markers for hypoxic cells: 2-nitroimidazoles with biotinylated 1-substituents.
    Hodgkiss RJ; Parrick J; Porssa M; Stratford MR
    J Med Chem; 1994 Dec; 37(25):4352-6. PubMed ID: 7996546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorescent markers for hypoxic cells. A study of novel heterocyclic compounds that undergo bio-reductive binding.
    Hodgkiss RJ; Begg AC; Middleton RW; Parrick J; Stratford MR; Wardman P; Wilson GD
    Biochem Pharmacol; 1991 Feb; 41(4):533-41. PubMed ID: 1705123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-selective antitumor agents. 10. bis(nitroimidazoles) and related Bis(nitroheterocycles): development of derivatives with higher rates of metabolic activation under hypoxia and improved aqueous solubility.
    Hay MP; Lee HH; Wilson WR; Roberts PB; Denny WA
    J Med Chem; 1995 May; 38(11):1928-41. PubMed ID: 7783125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flow cytometric evaluation of hypoxic cells in solid experimental tumours using fluorescence immunodetection.
    Hodgkiss RJ; Jones G; Long A; Parrick J; Smith KA; Stratford MR; Wilson GD
    Br J Cancer; 1991 Jan; 63(1):119-25. PubMed ID: 1989649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia.
    Hodgkiss RJ
    Anticancer Drug Des; 1998 Sep; 13(6):687-702. PubMed ID: 9755725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel fluorescent markers for hypoxic cells of naphthalimides with two heterocyclic side chains for bioreductive binding.
    Liu Y; Xu Y; Qian X; Liu J; Shen L; Li J; Zhang Y
    Bioorg Med Chem; 2006 May; 14(9):2935-41. PubMed ID: 16403640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel aliphatic N-oxide of naphthalimides as fluorescent markers for hypoxic cells in solid tumor.
    Yin H; Zhu W; Xu Y; Dai M; Qian X; Li Y; Liu J
    Eur J Med Chem; 2011 Jul; 46(7):3030-7. PubMed ID: 21550698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of novel 8-oxo-8H-cyclopenta[a]acenaphthylene-7-carbonitriles as long-wavelength fluorescent markers for hypoxic cells in solid tumor.
    Liu Y; Xu Y; Qian X; Xiao Y; Liu J; Shen L; Li J; Zhang Y
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1562-6. PubMed ID: 16403630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Nitroimidazole-tricarbocyanine conjugate as a near-infrared fluorescent probe for in vivo imaging of tumor hypoxia.
    Okuda K; Okabe Y; Kadonosono T; Ueno T; Youssif BG; Kizaka-Kondoh S; Nagasawa H
    Bioconjug Chem; 2012 Mar; 23(3):324-9. PubMed ID: 22335430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nitroimidazole-based bioreductive compounds bearing a quinazoline or a naphthyridine chromophore.
    Papadopoulou MV; Bloomer WD
    Anticancer Drugs; 2009 Jul; 20(6):493-502. PubMed ID: 19430289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel nitroheterocyclic hypoxic markers for solid tumor: synthesis and biological evaluation.
    Zhu W; Dai M; Xu Y; Qian X
    Bioorg Med Chem; 2008 Mar; 16(6):3255-60. PubMed ID: 18160298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-selective antitumor agents. 8. Bis(nitroimidazolyl)alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitisers.
    Hay MP; Wilson WR; Moselen JW; Palmer BD; Denny WA
    J Med Chem; 1994 Feb; 37(3):381-91. PubMed ID: 8308864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a second nitroimidazole redox centre on the accumulation of a hypoxia marker: synthesis and in vitro evaluation of 99mTc-labeled bisnitroimidazole propylene amine oxime complexes.
    Huang H; Zhou H; Li Z; Wang X; Chu T
    Bioorg Med Chem Lett; 2012 Jan; 22(1):172-7. PubMed ID: 22153341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorescent markers of hypoxic cells: a comparison of two compounds on three cell lines.
    Begg AC; Hodgkiss RJ; McNally NJ; Middleton RW; Stratford MR; Terry NH
    Br J Radiol; 1985 Jul; 58(691):645-54. PubMed ID: 3839428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electron-affinic sensitization VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers. 1976.
    Adams GE; Flockhart IR; Smithen CE; Stratford IJ; Wardman P; Watts ME
    Radiat Res; 2012 Aug; 178(2):AV183-9. PubMed ID: 22870968
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel 1-haloalkyl-2-nitroimidazole bioreductive alkylating agents.
    Heimbrook DC; Shyam K; Sartorelli AC
    Anticancer Drug Des; 1988 Mar; 2(4):339-50. PubMed ID: 3130072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-[2-(2-methyl-5-nitroimidazolyl)ethyl]-4-(2-nitroimidazolyl)butanamide (NSC 639862), a bisnitroimidazole with enhanced selectivity as a bioreductive drug.
    Moselen JW; Hay MP; Denny WA; Wilson WR
    Cancer Res; 1995 Feb; 55(3):574-80. PubMed ID: 7834627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of a range of novel nitro-aromatic radiosensitizers and bioreductive drugs.
    Fielden EM; Adams GE; Cole S; Naylor MA; O'Neill P; Stephens MA; Stratford IJ
    Int J Radiat Oncol Biol Phys; 1992; 22(4):707-11. PubMed ID: 1544842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.